Board of Directors
Stig Løkke Pedersen
Stig Løkke Pedersen
Elected to the Board of Directors in 2017 and Chair of the Board since 2020. Stig is regarded as an independent board member.
Special competencies
Stig has more than 35 years of strategic, commercial and leadership expertise from the life science industry, holding senior positions at H. Lundbeck and Ciba-Geigy.
Current positions
Chairman of the Board of Directors and member of the Board in several private and publicly listed biotechnology companies, including Dizlin AB, StemMedical and SSI Diagnostica. In addition, Stig is Operating Partner in the private equity fund Catacap.
Education
Stig holds an M.Sc. in Economics from Aalborg University, Denmark.
Nationality
Danish
Andrew J. Oakley
Andrew J. Oakley
Andrew J. Oakley was elected to the Board of Directors in 2019 and is regarded as an independent board member.
Special competencies
Andrew is a global executive with more than 30 years of financial and capital markets experience, holding positions as Chief Financial Officer of Actelion, Vectura PLC, Sosei Group Corporation, Autolus Therapeutics PLC and Theolytics Ltd.
Current positions
Andrew currently serves as Chief Financial Officer of TargImmune Therapeutics AG, and is a board member of Novaremed AG, Virometix AG and Onconetix Inc. (ONCO).
Education
Andrew holds a Bachelor of Economics degree from Macquarie University and an MBA from London Business School, United Kingdom. Andrew has been a member of the Australian Institute of Chartered Accountants since 1987.
Nationality
Australian
Dr. Peter Kristensen
Dr. Peter Kristensen
Peter Kristensen was elected to the Board of Directors in 2024 and is regarded as an independent board member.
Special competencies
Peter has more than 30 years of drug development and regulatory experience from Novo Nordisk, as Senior External Advisor with McKinsey & Co and as an independent consultant. At Novo Nordisk, Peter started as a research scientist, headed the development of Victoza (liraglutide) and was for 10+ years Senior Vice President of drug development, project management and global clinical operations.
Current positions
Independent consultant.
Education
Peter has a Medical Degree and a Medical Doctorate from University of Copenhagen, an E*MBA from SIMI (today part of CBS Executive) and is a member of the Danish Academy of Technical Sciences.
Nationality
Danish
Dr. Rasmus Toft-Kehler
Dr. Rasmus Toft-Kehler
Member of the Board, and not considered independent due to being Co-CEO as well as co-founder and major shareholder of UNION.
Special competencies
Extensive leadership and strategic development experience from founding and building companies in the life science industry. Before going into biotech, Rasmus worked in investment banks and in management consulting.
Current positions
Rasmus is the Co-CEO of UNION and co-founder of multiple companies. He is also board member at UTILITY Therapeutics.
Education
Rasmus holds a Ph.D. in Entrepreneurship from Copenhagen Business School and executive education from Harvard Business School.
Nationality
Danish
Dr. Morten Sommer
Dr. Morten Sommer
Member of the Board, and not considered independent due to being CSO as well as co-founder and shareholder of UNION.
Special competencies
Extensive research and development experience working within fields of drug development, industrial biotechnology and microbiome research. Morten has published more than 100 scientific publications and is an inventor of several issued patents.
Current positions
Morten is the Chief Scientific Officer of UNION and holds the position as Professor and Scientific Director at the Technical University
of Denmark. Morten is member of the board in Novonesis, Clinical-Microbiomics, SNIPR biome and UTILITY therapeutics.
Education
Morten holds a M.Sc. in Physics from University of Copenhagen and a Ph.D. in Biophysics from Harvard University from the laboratory of Professor George Church.
Nationality
Danish
